Medicine recalls
|
| |
| Canada: Recall: JAMP Telmisartan-HCT: Affected lot may contain higher dosage than the labelled dose |
| |
Health Canada announces that JAMP Pharma Corporation is recalling one lot of JAMP Telmisartan-HCT Tablet (telmisartan 80 mg/hydrochlorothiazide 12.5 mg) (lot number: EG22TCJ001) from retailers. Possible presence of tablets containing only the hydrochlorothiazide layer in the affected lot which may also result in a higher dosage than the labelled dose of 12.5 mg.
Please refer to the following website in Health Canada for details:
http://recalls-rappels.canada.ca/en/alert-recall/jamp-telmisartan-hct-affected-lots-may-contain-higher-dosage-labelled-dose
In Hong Kong, the above product is not a registered pharmaceutical product.
Ends/Thursday, Jan 25, 2024
Issued at HKT 15:30
|
| |
